Last Week in Event SPACE: Pharmaron, TOPIX Reorganisation, 2019 M&A Round-Up
Last Week in Event SPACE ... At a 33% A-H premium, there should be upside for Pharmaron Beijing Co Ltd-H (3759 HK)'s H shares when referenced...
411 Views
Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
490 Views
ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...
439 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
410 Views
Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading
Pharmaron, the second-largest contract research organization (CRO), raised USD 560 m at HKD 39.50/share. In this insight, we will cover the...
433 Views